Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy
Status:
Not yet recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
CIDP is a heterogeneous disease with variable responses to therapy. Recently, a distinctive
subgroup of patients with serum autoantibodies to the paranodal proteins contactin and
neurofascin have been identified. Although they present with active and serious disease,
multiple clinical reports suggest that these patients can be cured with a treatment that
depletes B cells and presumably eliminates pathogenic autoantibodies. However, beyond that
subgroup of CIDP patients, which CIDP patients might benefit from Rituximab and B cell
depletion is unknown. This Phase II study will treat 3 homogenous groups of 16 CIDP patients
each with Rituximab in order to determine if there are subgroups that can be taken off
current medications and put into long-term remission. The results from this study will be
used to design a future larger trial. Biomarkers including paranodal antibodies, serum
neurofilament light chains, anti-ganglioside antibodies will be obtained in order to learn
about disease pathogenesis and possibly target therapy